Your browser is no longer supported. Please, upgrade your browser.
Sunesis Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.86 Insider Own0.11% Shs Outstand15.93M Perf Week35.37%
Market Cap99.27M Forward P/E- EPS next Y-1.16 Insider Trans0.00% Shs Float13.74M Perf Month78.52%
Income-22.10M PEG- EPS next Q-0.28 Inst Own26.50% Short Float8.92% Perf Quarter318.90%
Sales2.20M P/S45.12 EPS this Y64.20% Inst Trans-33.25% Short Ratio0.61 Perf Half Y92.27%
Book/sh1.19 P/B4.47 EPS next Y-4.50% ROA-72.30% Target Price3.25 Perf Year-48.35%
Cash/sh1.39 P/C3.82 EPS next 5Y- ROE-179.10% 52W Range1.12 - 11.30 Perf YTD167.34%
Dividend- P/FCF- EPS past 5Y42.60% ROI-109.80% 52W High-52.92% Beta2.38
Dividend %- Quick Ratio7.70 Sales past 5Y-18.40% Gross Margin- 52W Low375.00% ATR0.59
Employees24 Current Ratio7.70 Sales Q/Q- Oper. Margin- RSI (14)80.80 Volatility24.66% 14.11%
OptionableYes Debt/Eq0.00 EPS Q/Q48.50% Profit Margin- Rel Volume34.85 Prev Close4.28
ShortableYes LT Debt/Eq0.00 EarningsNov 16 AMC Payout- Avg Volume2.01M Price5.32
Recom3.00 SMA2065.04% SMA50100.09% SMA200106.25% Volume70,014,049 Change24.30%
Feb-23-21Upgrade Oppenheimer Perform → Outperform $12
Jun-24-20Downgrade Oppenheimer Outperform → Perform
Mar-11-20Downgrade Wells Fargo Overweight → Equal Weight $3 → $1
Dec-20-18Initiated H.C. Wainwright Neutral
Dec-11-17Upgrade Wells Fargo Market Perform → Outperform
Dec-05-17Downgrade Wells Fargo Outperform → Market Perform
Jul-29-16Upgrade Wells Fargo Market Perform → Outperform
Jul-24-15Downgrade ROTH Capital Buy → Sell $5.50 → $1
Jul-24-15Downgrade Cantor Fitzgerald Buy → Hold
Jun-15-15Reiterated ROTH Capital Buy $4 → $5.50
May-05-15Reiterated ROTH Capital Buy $4.30 → $4
Dec-15-14Upgrade ROTH Capital Neutral → Buy $2.30 → $4.30
Dec-09-14Reiterated ROTH Capital Neutral $1.30 → $2.30
Oct-07-14Downgrade ROTH Capital Buy → Neutral $15 → $1.30
Oct-07-14Downgrade RBC Capital Mkts Outperform → Sector Perform $9 → $3
Jun-12-14Initiated UBS Buy $14
Sep-11-12Reiterated Cantor Fitzgerald Buy $6 → $8
May-29-12Upgrade RBC Capital Mkts Sector Perform → Outperform $3 → $5
Apr-13-12Initiated Cantor Fitzgerald Buy $6
Mar-06-12Initiated Canaccord Genuity Buy $4
Feb-24-21 04:05PM  
Feb-16-21 12:56PM  
Feb-11-21 04:05PM  
Jan-08-21 08:30PM  
Jan-07-21 05:58PM  
Jan-05-21 11:28AM  
Dec-30-20 08:49PM  
Dec-29-20 07:00PM  
Dec-19-20 04:55PM  
Dec-18-20 10:16PM  
Dec-17-20 02:49PM  
Dec-12-20 08:52AM  
Dec-11-20 08:55PM  
Dec-07-20 08:30AM  
Dec-05-20 07:20AM  
Dec-04-20 09:13PM  
Dec-03-20 05:17PM  
Dec-02-20 08:31PM  
Dec-01-20 11:36AM  
Nov-30-20 08:34PM  
Nov-16-20 04:05PM  
Nov-09-20 07:00AM  
Oct-12-20 07:00AM  
Sep-03-20 12:19PM  
Sep-02-20 12:48PM  
Aug-11-20 06:18PM  
Aug-10-20 11:12AM  
Aug-04-20 07:00AM  
Jul-29-20 09:05AM  
Jul-28-20 04:07PM  
Jul-23-20 11:30AM  
Jul-07-20 04:01PM  
Jul-05-20 08:55PM  
Jun-23-20 07:30AM  
Jun-18-20 08:57AM  
May-14-20 02:24PM  
May-07-20 04:05PM  
Apr-30-20 07:00AM  
Apr-09-20 06:30PM  
Apr-02-20 11:30AM  
Mar-17-20 11:30AM  
Mar-13-20 12:56PM  
Mar-10-20 04:05PM  
Mar-03-20 07:00AM  
Feb-25-20 04:05PM  
Dec-19-19 06:10PM  
Dec-07-19 08:35AM  
Dec-06-19 07:39AM  
Dec-05-19 11:41AM  
Dec-02-19 08:40PM  
Nov-12-19 04:05PM  
Nov-08-19 07:00AM  
Nov-06-19 09:16AM  
Oct-29-19 07:00AM  
Oct-18-19 10:23AM  
Oct-16-19 04:59PM  
Sep-19-19 07:00AM  
Sep-13-19 11:50AM  
Sep-05-19 10:38AM  
Aug-28-19 07:00AM  
Aug-10-19 06:18PM  
Aug-09-19 07:20AM  
Aug-07-19 04:05PM  
Jul-31-19 07:00AM  
Jul-15-19 02:38PM  
Jul-11-19 06:17AM  
Jul-10-19 04:01PM  
Jul-08-19 08:30AM  
Jun-17-19 08:51AM  
Jun-15-19 11:30AM  
Jun-14-19 08:47AM  
Jun-08-19 04:09PM  
May-17-19 12:24AM  
May-08-19 05:52PM  
May-01-19 09:26AM  
Apr-29-19 04:05PM  
Apr-04-19 02:35PM  
Apr-03-19 07:00AM  
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of hematologic and solid cancers. Its lead product candidate is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; various other partnered programs, such as TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, an anti-cancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. It has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of PDK1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gullotta TinaVP, FinanceMay 29Buy0.336,0001,98920,500Jun 05 03:18 PM